Results 221 to 230 of about 16,017 (247)

Food-drug interactions of novel drugs used in cardiologic and diabetic patients - a PRISMA scoping review. [PDF]

open access: yesFront Pharmacol
Pawłowska I   +4 more
europepmc   +1 more source

Lipid Nanoparticle Delivery of CAR276 mRNA Enables Antigen-Specific Cytotoxicity in T Cells Against Glioblastoma Cells. [PDF]

open access: yesBiomedicines
Zahedipour F   +9 more
europepmc   +1 more source

Open Systems Pharmacology Community Conference (OSP-CC) Proceedings 2025. [PDF]

open access: yesCPT Pharmacometrics Syst Pharmacol
Cordes H   +35 more
europepmc   +1 more source

Six Years of Progress in the Oral Biopharmaceutics Area – A Summary From the IMI OrBiTo Project [PDF]

open access: yesEuropean Journal of Pharmaceutics and Biopharmaceutics, 2020
OrBiTo was a precompetitive collaboration focused on the development of the next generation of Oral Biopharmaceutics Tools. The consortium included world leading scientists from nine universities, one regulatory agency, one non-profit research ...
Anette Müllertz   +2 more
exaly   +2 more sources

Classification of WHO Essential Oral Medicines for Children Applying a Provisional Pediatric Biopharmaceutics Classification System

open access: yesPharmaceutics, 2019
The objective was using the Essential Medicines List for children by the World Health Organization (WHO) to create a pediatric biopharmaceutics classification system (pBCS) of the oral drugs included in the Essential Medicines List by the World Health ...
Marival Bermejo   +2 more
exaly   +3 more sources

Towards the Development of a Paediatric Biopharmaceutics Classification System: Results of a Survey of Experts [PDF]

open access: yesInternational Journal of Pharmaceutics, 2016
The aim of this research survey was to understand current global thinking around the need for and development of a paediatric biopharmaceutics classification system (pBCS) to be used for the development of paediatric medicines and regulatory purposes (e ...
Sandra Klein   +2 more
exaly   +5 more sources

Home - About - Disclaimer - Privacy